Continuous Glucose Monitors Beyond Diabetes: Reading the Evidence Carefully

Continuous glucose monitors (CGMs) started as tools for people with diabetes. Today they also appear in wellness programs aimed at people without the condition. The technology is the same. The evidence is not.

This article separates what is well established from what is still open, without offering advice for any individual.

How a CGM works

A CGM uses a small sensor worn on the body. A thin filament sits just under the skin and measures glucose in interstitial fluid, the fluid between cells. A transmitter sends readings to a phone or reader every few minutes, producing a near-continuous curve instead of a few fingerstick values per day.

Why lag matters

Glucose reaches the interstitial fluid after it appears in the blood, so sensor values can trail blood values by some minutes. During rapid changes the gap can be noticeable. This is one reason device labeling and clinical guidance often describe when a confirmatory blood measurement is appropriate.

Where the evidence is strongest

For people with diabetes who use insulin, CGMs give clinicians and patients a detailed picture of glucose over days and weeks. Patterns such as overnight lows or post-meal peaks are hard to see with occasional fingersticks.

Many systems provide:

• Alarms for low or high readings.
• Trend arrows that show the direction of change.
• Summary reports that clinicians use during visits.

These features connect to clinical decisions that clinicians and patients already know how to make. That link between measurement and action is what supports their use.

The open questions in people without diabetes

Glucose in healthy people rises and falls through the day. It changes with food, sleep, stress, activity and illness. A CGM will show this variation, and that is where interpretation becomes difficult.

Seeing a number move is not the same as knowing what it means for health.

Researchers continue to study what ranges and patterns are typical in people without diabetes, and whether CGM-guided changes in behavior lead to better outcomes. Today the evidence for that second question is limited. Without agreed reference ranges, a normal fluctuation can look like a problem to a wearer, which may cause worry without benefit.

Wellness claims versus clinical claims

Some products are sold with general wellness messages and no specific clinical claim. That affects how they are regulated, and it affects what a user can expect from the product. Readers can compare the labeling of a product with the statements used in its marketing.

Accuracy and its limits

CGM accuracy is described by statistical measures against reference blood values, and it varies by device, by sensor and by glucose range. Accuracy tends to be lower at very low and very high values and during fast changes. Factors such as sensor placement, hydration and certain substances can affect readings. Labeling lists known interferences, and those are worth reading.

What to ask about any CGM program

For an organization that offers CGMs to a population, a few questions help:

1. What is the intended use stated in the device labeling?
2. Is there a clinician in the loop who can interpret results?
3. What will the program do with the data, and who owns it?
4. How will the program measure whether participants benefit?

Looking ahead

Sensors continue to improve, and integration with insulin delivery devices is changing diabetes care. For people without diabetes, better studies are needed to define what the data means. Until then, a cautious position is reasonable: CGMs are strong tools where a clinical decision follows the measurement, and an open research question where it does not.